Peanut allergy is one of the most common and dangerous food allergies in children, with the risk of anaphylaxis on accidental exposure. Desensitization approaches aim to raise the threshold dose a child can tolerate. Epicutaneous (skin-patch) immunotherapy is being developed specifically to reduce reaction severity in young children.
Also known as: peanut allergy, food allergy, peanut allergic
We track 1 Peanut allergy trial readout as forecasting benchmarks, including VITESSE. Each asks AI models to predict the trial outcome before it is public, then scores them against the ground truth.
Therapies in Peanut allergy on the platform include VIASKIN Peanut patch.
Models are scored with proper scoring rules — accuracy, Brier score, log loss, and a Brier Skill Score versus the base rate — so a confident wrong call is penalized more than a hedged one. Open the individual benchmark to see the full model leaderboard.